Literature DB >> 9135219

Hepatitis C virus infection in 'primary' Sjögren's syndrome: prevalence and clinical significance in a series of 90 patients.

M García-Carrasco1, M Ramos, R Cervera, J Font, J Vidal, F J Muñoz, C Miret, G Espinosa, M Ingelmo.   

Abstract

OBJECTIVES: To determine the prevalence and clinical significance of hepatitis C virus (HCV) infection in a large cohort of patients with "primary' Sjögren's syndrome (SS).
METHODS: 90 consecutive patients (83 female and seven male) were included, with a mean age of 62 years (range 31-80) who prospectively visited our unit. All patients fulfilled the European Community criteria for SS and underwent a complete history, physical examination, as well as biochemical and immunological evaluation for liver disease. Serum from all patients was tested for antibodies to HCV by third generation enzyme linked immunoassay and positivity was confirmed by polymerase chain reaction.
RESULTS: Antibodies to HCV were present in 13 (14%) patients with 'primary' SS. When compared with patients without HCV infection, patients with HCV infection presented a higher prevalence of hepatic involvement, (100% v 8%, p < 0.05). Transcutaneous liver biopsy was performed in five patients with HCV infection, and specimens obtained showed in all cases a chronic active hepatitis with varying degrees of portal inflammation.
CONCLUSION: HCV infection is frequent in patients with "primary' SS and liver involvement is presented in all these patients. The possible pathogenic role of HCV infection in these patients is still unclear.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135219      PMCID: PMC1752339          DOI: 10.1136/ard.56.3.173

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  16 in total

1.  Is hepatitis C virus a sialotropic virus?

Authors:  M Ramos-Casals; M Garcia-Carrasco; R Cervera; J Font
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 2.  Hepatic manifestations of autoimmune rheumatic diseases.

Authors:  S Abraham; S Begum; D Isenberg
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

3.  Anti-ENA antibodies in patients with chronic hepatitis C virus infection.

Authors:  E D'Amico; C Palazzi; P Cacciatore; A Canelli; G Ursitti; L Cosentino; V Dogali; G Riario-Sforza; F Capani
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

4.  In situ detection of hepatitis C virus RNA in salivary glands.

Authors:  J J Arrieta; E Rodríguez-Iñigo; N Ortiz-Movilla; J Bartolomé; M Pardo; F Manzarbeitia; H Oliva; D M Macías; V Carreño
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

5.  Involvement of the liver in rheumatic diseases.

Authors:  Hiromasa Ohira; Kazumichi Abe; Atsushi Takahashi
Journal:  Clin J Gastroenterol       Date:  2011-11-26

6.  Anti-ENA antibody profiles in patients with hepatitis C virus infection.

Authors:  Christine M Litwin; Angela R Rourk
Journal:  J Clin Lab Anal       Date:  2017-06-12       Impact factor: 2.352

7.  Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases.

Authors:  S Aslanidis; T Vassiliadis; A Pyrpasopoulou; I Douloumpakas; C Zamboulis
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 3.650

Review 8.  Immune Components of Liver Damage Associated with Connective Tissue Diseases.

Authors:  Aziz A Chentoufi; Youri A Serov; Mansour Alazmi; Kamaldeen Baba
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

Review 9.  Genetics and autoantibodies.

Authors:  Carlo Perricone; Nancy Agmon-Levin; Fulvia Ceccarelli; Guido Valesini; Juan-Manuel Anaya; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2013-07       Impact factor: 4.505

10.  The liver is a common non-exocrine target in primary Sjögren's syndrome: a retrospective review.

Authors:  Mariana J Kaplan; Robert W Ike
Journal:  BMC Gastroenterol       Date:  2002-09-13       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.